In both the A549 and H1299-MSLNLow tumor models, MSLN CAR-T cells and NKG2D/CD28&MSLN CAR-T cells demonstrated significant tumor regression compared to the non-transduced T cell control group, as evidenced by reduced tumor volumes and in vivo imaging. This evidence concerns the gene CD28 and neoplasm.